Syncona Limited

Issue of shares pursuant to incentive scheme and PDMR dealings

19 July 2024

Syncona Ltd (the "Company"), a leading life science investor focused on creating, building and scaling global leaders in life science, today announces that a total of 407,966 new ordinary shares (representing approximately 0.06% of the Company's existing issued ordinary shares, excluding shares held in treasury) will be issued in satisfaction of realisations under the Company's long term incentive scheme.  The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. In accordance with the rules of the incentive scheme, the number of ordinary shares to be issued has been calculated using the closing mid-market price on 17 July, 2024, £1.25.

In accordance with the rules of the incentive scheme, ordinary shares delivered on realisation may not be sold or transferred by the recipient for a period of one year following the realisation date.

The issue of shares includes the following shares to be issued to senior members of the Syncona Investment Management Limited (SIML) leadership team:

Application will be made to the Financial Conduct Authority for the shares to be admitted to the Official List, and to the London Stock Exchange for the shares to be admitted to trading and it is expected that dealings will commence in the new ordinary shares on 24 July 2024.

Notification of transactions by Persons Discharging Managerial Responsibilities ("PDMRs") are set out below.

[ENDS]

Enquiries

Syncona Ltd

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 20 3981 7940

FTI Consulting

Ben Atwell / Tim Stamper

Tel: +44 (0) 20 3727 1000 

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.

We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com